Healthcare -
Biotechnology - NASDAQ - US
$ 3.32
0.61 %
$ 86.3 M
Market Cap
-0.3
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Senti Biosciences, Inc.
| Net Income | -52.8 M |
| Depreciation & Amortization | 5.85 M |
| Capital Expenditures | -26 K |
| Stock-Based Compensation | 1.76 M |
| Change in Working Capital | 4.04 M |
| Others | 3.05 M |
| Free Cash Flow | -41.4 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (52.8) | (71.1) | (58.2) | (55.3) | (19.9) | (21.2) |
| Depreciation & Amortization | 5.9 | 5.4 | 3.9 | 3.0 | 2.0 | 1.4 |
| Deferred Income Tax | 0 | 0 | 0 | 22 K | 0.2 | (0.3) |
| Stock Based Compensation | 1.8 | 9.7 | 16.4 | 2.3 | 0.3 | 0.2 |
| Other Operating Activities | (0.3) | (1.1) | (10.9) | 14.7 | (5.0) | 1.4 |
| Change in Working Capital | 4.0 | 4.7 | 13.9 | 0.6 | (1.8) | 0.1 |
| Cash From Operations | (41.4) | (52.4) | (34.9) | (34.6) | (24.2) | (18.4) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 26 K | (12.0) | (41.4) | (5.5) | (1.2) | (2.0) |
| Other Items | 60 K | 42.1 | (40.6) | 0 | 12.5 | 5.7 |
| Cash From Investing Activities | 34 K | 30.1 | (82.0) | (5.5) | 11.4 | 3.8 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | (0.1) | 5.2 | 0 | 8.0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.7 | 0.4 | 112.6 | 68.4 | 30.1 | 14.0 |
| Cash From Financing Activities | 53.7 | 0.8 | 118.6 | 68.4 | 38.1 | 14.0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 12.4 | (21.5) | 1.7 | 28.3 | 25.2 | 5.8 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (41.4) | (64.4) | (76.3) | (40.2) | (25.3) | (20.4) |